Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial

Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial

Abstract Background Antipsychotic-induced Weight Gain (AiWG) is a debilitating and common adverse effect of antipsychotics. AiWG negatively impacts life expectancy, quality of life, treatment adherence, likelihood of developing type-2 diabetes and readmission. Treatment of AiWG is currently challeng...

Full description

Bibliographic Details
Main Authors: Nini de Boer, Sinan Guloksuz, Caroline van Baal, Leonie Willebrands, Jeroen Deenik, Christiaan H. Vinkers, Inge Winter-van Rossum, Janneke Zinkstok, Ingeborg Wilting, Jasper B. Zantvoord, Frank Backx, Wilma E. Swildens, Marieke Schouw, Jan Bogers, Folkwin Hulshof, Rudolf de Knijff, Peter Duindam, Mike Veereschild, Maarten Bak, Geert Frederix, Lieuwe de Haan, Jim van Os, Wiepke Cahn, Jurjen J. Luykx
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Psychiatry
Subjects:
Antipsychotic-induced weight gain (AiWG)
Schizophrenia
Metformin
Lifestyle
Online Access:https://doi.org/10.1186/s12888-020-02992-4

Internet

https://doi.org/10.1186/s12888-020-02992-4

Similar Items